237 related articles for article (PubMed ID: 33044176)
1. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
[TBL] [Abstract][Full Text] [Related]
2. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington KD; Bourgeat P; Salvado O; Darby D; Snyder PJ; Bush AI; Martins RN; Masters CL; Rowe CC; Nathan PJ; Maruff P;
Neurobiol Aging; 2013 Nov; 34(11):2457-64. PubMed ID: 23769397
[TBL] [Abstract][Full Text] [Related]
3. Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease.
Gomar JJ; Conejero-Goldberg C; Huey ED; Davies P; Goldberg TE;
Neurobiol Aging; 2016 Mar; 39():165-73. PubMed ID: 26923413
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
[TBL] [Abstract][Full Text] [Related]
5. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
[TBL] [Abstract][Full Text] [Related]
6. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
Lim YY; Hassenstab J; Cruchaga C; Goate A; Fagan AM; Benzinger TL; Maruff P; Snyder PJ; Masters CL; Allegri R; Chhatwal J; Farlow MR; Graff-Radford NR; Laske C; Levin J; McDade E; Ringman JM; Rossor M; Salloway S; Schofield PR; Holtzman DM; Morris JC; Bateman RJ;
Brain; 2016 Oct; 139(Pt 10):2766-2777. PubMed ID: 27521573
[TBL] [Abstract][Full Text] [Related]
7. Impact of APOE and BDNF Val66Met Gene Polymorphisms on Cognitive Functions in Patients with Amnestic Mild Cognitive Impairment.
Cechova K; Andel R; Angelucci F; Chmatalova Z; Markova H; Laczó J; Vyhnalek M; Matoska V; Kaplan V; Nedelska Z; Ward DD; Hort J
J Alzheimers Dis; 2020; 73(1):247-257. PubMed ID: 31771052
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
[TBL] [Abstract][Full Text] [Related]
9. Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism.
Nielsen HM; Chen K; Lee W; Chen Y; Bauer RJ; Reiman E; Caselli R; Bu G
Alzheimers Res Ther; 2017 Jan; 9(1):5. PubMed ID: 28137305
[TBL] [Abstract][Full Text] [Related]
10. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.
Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington K; Bourgeat P; Bush AI; Martins RN; Masters CL; Rowe CC; Maruff P;
PLoS One; 2014; 9(1):e86498. PubMed ID: 24475133
[TBL] [Abstract][Full Text] [Related]
11. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
12. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
Chung JK; Plitman E; Nakajima S; Caravaggio F; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Shinagawa S; Patel R; Chakravarty MM; Graff-Guerrero A;
J Alzheimers Dis; 2017; 58(3):747-762. PubMed ID: 28505977
[TBL] [Abstract][Full Text] [Related]
13. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
[TBL] [Abstract][Full Text] [Related]
15.
Boots EA; Schultz SA; Clark LR; Racine AM; Darst BF; Koscik RL; Carlsson CM; Gallagher CL; Hogan KJ; Bendlin BB; Asthana S; Sager MA; Hermann BP; Christian BT; Dubal DB; Engelman CD; Johnson SC; Okonkwo OC
Neurology; 2017 May; 88(22):2098-2106. PubMed ID: 28468845
[TBL] [Abstract][Full Text] [Related]
16. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846
[TBL] [Abstract][Full Text] [Related]
17. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
18. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
19. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
[TBL] [Abstract][Full Text] [Related]
20. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
